Results 61 to 70 of about 812,191 (301)

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. [PDF]

, 2017
T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy ...
Ackerman, Ahmed, Ansell, Araki, Ascierto, Beatty, Beatty, Blagih, Borkner, Brahmer, Brandacher, Brentjens, Brentjens, Bridgeman, Brocker, Brudno, Buck, Buckanovich, Burnette, Butler, Butler, Carpenito, Caruana, Caruso, Chang, Chang, Chen, Chen, Chen, Cherkassky, Chmielewski, Church, Colegio, Cordoba, Cretenet, Crompton, Cui, Curiel, Curran, Deaglio, Demaria, Doedens, Facciabene, Fesnak, Finney, Fischer, Fousek, Fox, Frauwirth, Frauwirth, Fridman, Fuertes, Gabrilovich, Gajewski, Gajewski, Galon, Gargett, Gattinoni, Gattinoni, Gattinoni, Geiger, Geissmann, Gill, Gobert, Govers, Gracias, Grada, Gross, Gross, Gubin, Gubser, Guest, Guppy, Hall, Hamanishi, Han, Harlin, Herrera, Hinrichs, Hinrichs, Ho, Hodi, Hombach, Hombach, Hombach, Hsu, Huang, Hudecek, Hwang, Iida, Ino, Irving, Italiani, James, Jass, Jensen, Jensen, Ji, Jones, Joyce, June, Justus, Kahlon, Kawalekar, Kerkar, Kershaw, Kershaw, Khalil, Khalil, Klebanoff, Klebanoff, Klebanoff, Klug, Lamers, Lanitis, Lanitis, Larkin, Le, Le, Lee, Li, Lipson, Liu, Liu, Lochner, Long, Louis, Lugli, Lunt, MacIver, Mahoney, Martinez-Forero, Marvel, Maude, Maus, Maus, Mellor, Menetrier-Caux, Mikucki, Miller, Mittal, Moon, Morgan, Morgan, Morsut, Motz, Motz, Motzer, Muniappan, Munn, Munn, Munn, Murdoch, Nghiem, Niederman, Noman, Okamoto, Otsuji, O’Sullivan, O’Sullivan, Palazón, Palmer, Pameijer, Pandiyan, Paolino, Pardoll, Parry, Patsoukis, Pearce, Pegram, Peng, Peng, Pipkin, Pluta, Porter, Powles, Prosser, Rabinovich, Rathmell, Restifo, Rizvi, Rodriguez, Rodriguez, Rosenberg, Rosenberg, Roybal, Salerno, Sallusto, Santoro, Savoldo, Scharping, Schmid, Schwartz, Semenza, Sharpe, Sikalidis, Sinclair, Singh, Sivan, Smith, Snyder, Sommermeyer, Spranger, Spranger, Spranger, Srivastava, Stromnes, Suarez, Sukumar, Sukumar, Tamada, Tan, Taylor, Terakura, Topalian, Topalian, Topalian, Torikai, Tran, Tumeh, Turatti, Urbanska, Uyttenhove, van der Merwe, van der Waart, van der Windt, van der Windt, van der Windt, van Rooij, Vander Heiden, Vuillefroy de Silly, Vuillefroy de Silly, Vétizou, Waickman, Wang, Wang, Wang, Wang, Wang, Warburg, Wherry, Willemsen, Wing, Wofford, Wu, Xu, Yang, Yang, Yaqoob, Zhang, Zhang, Zhang, Zheng   +252 more
core   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Molecular Therapy: Oncology
Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼
Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G. Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer   +9 more
doaj   +1 more source

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia [PDF]

, 2015
Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose limiting toxicities.
Anne Angiolillo, Haneen Shalabi, Terry J. Fry   +2 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source

A methionine‐lined active site governs carbocation stabilization and product specificity in a bacterial terpene synthase

FEBS Letters, EarlyView.
This study reveals a unique active site enriched in methionine residues and demonstrates that these residues play a critical role by stabilizing carbocation intermediates through novel sulfur–cation interactions. Structure‐guided mutagenesis further revealed variants with significantly altered product profiles, enhancing pseudopterosin formation. These
Marion Ringel, Carl P. O. Helmer, Shani Zev, Ronja Driller, Emily Buhr, Markus Reinbold, Renana Schwartz, Gabriel Foley, Mikael Boden, Daniel Garbe, Gerhard Schenk, Dan Thomas Major, Bernhard Loll, Thomas Brück   +13 more
wiley   +1 more source

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES

Mediterranean Journal of Hematology and Infectious Diseases
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes.
Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone   +4 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source